glp-1/gip receptor agonists PDB-101: Molecule of the Month: GLP-1 Physiology and clinical applications of
Description
After weekly subcutaneous injection, EX was slowly released from the microspheres by diffusion and microsphere rupture and reached a stable plasma concentration about 6-8 weeks after treatment (114)
Pharmacotherapy 37 , 927943 (2017)
Interestingly, administration of liraglutide in mice with selective disruption of the cardiomyocyte GLP-1R ( Glp1r CM/ ) generated from MerCreMer transgenic mice expressing tamoxifen-inducible Cre driven by the -myosin heavy chain promoter, still produced robust cardioprotection and increased survival, suggesting that cardiomyocyte GLP-1R activation is not required for adaptive responses to ischemic and cardiomyopathic injury mediated by liraglutide (Ussher et al
Distinctive metabolomics patterns associated with insulin resistance and type 2 diabetes mellitus
S.HopkinsonM.Al-JazzarA.RouxJ
AM: Formal Analysis, Methodology, Writing review & editing
